Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
← catalyst calendarNCT07007065 · readout ≤ 2,416 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
561estimated
Sites
131
Countries
Austria, Belgium, Bulgaria +14
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-05 | actual | When the study began enrolling |
| Primary completion | Mar 2033 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2033 | estimated | The whole study's end, after follow-up |
| First posted | 2025-06-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Neovascular Age-related Macular Degeneration
Interventions
- Drug: Surabgene Lomparvovec (ABBV-RGX-314) — also filed as Surabgene Lomparvovec
- Drug: Ranibizumab Control
Primary outcomes
what the primary-completion date above is the date OFAnnualized intravitreal anti-VEGF injection rate
measured Up to Week 54
Number of Participants Experiencing Adverse Events
measured Up to 5 years
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed